In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mast Therapeutics, Inc.

https://savarapharma.com/

Latest From Mast Therapeutics, Inc.

Glenmark’s Ryaltris To Reach Western Europe Following Approvals

Glenmark is toasting another launch for the company’s Ryaltris novel treatment for allergic rhinitis, this time with plans to roll the product out in 17 countries across western Europe.

Approvals Launches

The Drugs That Could Face US Generic/Biosimilar Competition In 2021

Other expected generics include Viatris' Perforomist (formoterol fumarate), Pfizer's Sutent (sunitinib), Sanofi's Jevtana (cabazitaxel) and possibly Boehringer Ingelheim's Pradaxa.

Biosimilars Generic Drugs

Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights

Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio

Deals M & A

Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals

Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.

Financing Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Other Names / Subsidiaries
    • Adventrx Pharmaceuticals, Inc.
    • Aires Pharmaceuticals, Inc.
    • SynthRx, Inc.
UsernamePublicRestriction

Register